Khurana Kiranpreet, Gilligan Timothy D, Stephenson Andrew J
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Indian J Urol. 2010 Jan-Mar;26(1):108-14. doi: 10.4103/0970-1591.61228.
Currently, the outcome of patients with intermediate-and poor-risk germ cell tumors at diagnosis is optimized by the use of risk-appropriate chemotherapy and post-chemotherapy surgical resection of residual masses. Currently, there is no role for high-dose chemotherapy in the first-line setting. Patients who progress on first-line chemotherapy or who relapse after an initial complete response also have a poor prognosis. In the setting of early relapse, the standard approach at most centers is conventional-dose, ifosfamide-based regimens and post-chemotherapy resection of residual masses. The treatment of patients with late relapse is complete surgical resection whenever feasible. Salvage chemotherapy for late relapse may be used prior to surgery in patients where a complete resection is not feasible. A complete surgical resection of all residual sites of disease after chemotherapy is critical for the prevention of relapse and the long-term survival of patients with advanced germ cell tumors.
目前,通过使用风险适配的化疗以及化疗后对残留肿块进行手术切除,可优化诊断时为中低风险生殖细胞肿瘤患者的治疗结局。目前,一线治疗中不采用高剂量化疗。一线化疗进展或初始完全缓解后复发的患者预后也较差。在早期复发的情况下,大多数中心的标准方法是采用基于异环磷酰胺的常规剂量方案以及化疗后对残留肿块进行切除。对于晚期复发患者,只要可行,治疗方法是完全手术切除。对于无法进行完全切除的患者,在手术前可使用挽救性化疗治疗晚期复发。化疗后对所有疾病残留部位进行完全手术切除对于预防晚期生殖细胞肿瘤患者复发和长期生存至关重要。